Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xenetic Biosciences Inc
(NQ:
XBIO
)
4.320
+0.510 (+13.39%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Sep 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xenetic Biosciences Inc
< Previous
1
2
3
4
5
Next >
12 Health Care Stocks Moving In Monday's Intraday Session
Today 12:30 EDT
Via
Benzinga
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
September 11, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
Via
ACCESSWIRE
XBIO Stock Earnings: Xenetic Biosciences Meets EPS, Beats Revenue for Q2 2024
August 13, 2024
XBIO stock results show that Xenetic Biosciences met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Xenetic Biosciences, Inc. Announces Executive Leadership Transition
May 22, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
May 10, 2024
Via
ACCESSWIRE
Xenetic Biosciences: Q3 Earnings Insights
November 10, 2023
Via
Benzinga
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
October 11, 2023
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results
August 11, 2023
Via
ACCESSWIRE
XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q1 2024
May 09, 2024
XBIO stock results show that Xenetic Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q4 2023
March 22, 2024
XBIO stock results show that Xenetic Biosciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
March 22, 2024
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
January 17, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Intraday Session
December 05, 2023
Via
Benzinga
Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
November 10, 2023
Via
ACCESSWIRE
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
July 05, 2023
Via
ACCESSWIRE
Lack Of Catalysts Prompts Analyst To Downgrade Xenetic Biosciences
May 16, 2023
Via
Benzinga
Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023
Via
ACCESSWIRE
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
Via
ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
June 20, 2023
Gainers
Via
Benzinga
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
May 15, 2023
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash.
Via
Benzinga
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
May 03, 2023
Via
ACCESSWIRE
12 Health Care Stocks Moving In Friday's Intraday Session
May 12, 2023
Via
Benzinga
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
May 12, 2023
Via
ACCESSWIRE
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development
May 04, 2023
Via
ACCESSWIRE
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention
April 13, 2023
U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of...
Via
Benzinga
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules
April 13, 2023
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug.
Via
Benzinga
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
April 12, 2023
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this...
Via
Benzinga
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
April 11, 2023
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 11, 2023
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.